Japan Clears First Human Genetic Diagnostic Reagent For Marketing
This article was originally published in PharmAsia News
Japan's Health Ministry cleared for production the first human genetic diagnostic reagent to be made in the country. Sekisui Medical, a subsidiary of Sekisui Chemical, got approval for the product designed to determine if irinotecan hydrochloride drugs would have severe side effects for cancer patients. Sekisui plans to sell the reagent as a general diagnostic test as early as next spring. Some patients experience severe diaarhea and vomiting after taking the drug. (Click here for more - a subscription may be required
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.